Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 15.80
Day High 15.88
Open:15.88
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

FEATURE-EMPTY
Description
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
BusinessWire - 1 hour ago
BusinessWire - CMTX
1 hour ago
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced thatPamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference onTuesday, June 25, 2019at3:20 p.m. ET.
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
BusinessWire - Fri Jun 7, 7:00AM CDT
BusinessWire - CMTX
Fri Jun 7, 7:00AM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019 at 2:00 p.m. PT (5:00 p.m. ET).
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
BusinessWire - Fri May 17, 1:01PM CDT
BusinessWire - CMTX
Fri May 17, 1:01PM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo. These data supported the initiation of a Phase 1 program of mRNA-1944 against chikungunya virus in January 2019 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of mRNA-1944 via intravenous infusion in healthy adults.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 15.28 +3.73% increase
on 06/17/19
Period Open:23.08
Price movement based on the high, low and last over the given period.
23.60 -32.84% decrease
on 05/20/19
-7.23 (-31.33%) decrease
since 05/17/19
3-Month 15.28 +3.73% increase
on 06/17/19
Period Open:22.18
Price movement based on the high, low and last over the given period.
29.79 -46.79% decrease
on 04/08/19
-6.33 (-28.54%) decrease
since 03/18/19
52-Week 13.03 +21.64% increase
on 12/26/18
Period Open:18.60
Price movement based on the high, low and last over the given period.
29.79 -46.79% decrease
on 04/08/19
-2.75 (-14.78%) decrease
since 12/07/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).